Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BSI 082

Next Previous
Drug Profile

BSI 082

Alternative Names: BSI-082

Latest Information Update: 04 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biosion
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Phagocyte stimulants; SIRPA protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 25 Jul 2025 Biosion in collaboration with The University of Texas Health Science Center plans a phase I trial for Solid tumours (Combination therapy, Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) (IV, Infusion), in August 2025 (NCT07086768)
  • 24 Jan 2024 Biosion receives IND approval from the U.S. Food and Drug Administration (US FDA) for BSI 082 for solid tumours
  • 12 Sep 2022 Biosion plans to file an IND application for Solid tumours in second half of 2023 (Biosion pipeline, September 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top